Novavax (NASDAQ: NVAX) announced positive top-line data from a Phase 2 clinical trial of its RSV F-protein recombinant nanoparticle vaccine ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments Momentum Movers

Novavax (NVAX) PT Raised to $17 at Piper Jaffray Following Positive Phase II Elderly RSV DataAugust 11, 2015 8:35 AM Novavax (NVAX) Tops Q2 EPS by 1cAugust 10, 2015 4:16 PM Novavax Announces Positive Top-Line Data from Phase 2 RSV F-Protein Vaccine Clinical Trial in Older AdultsAugust 10, 2015 4:10 PM